Clinical Trials
14 trialsNCT05377827 2026-05-06
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
Phase 1 Active not recruiting
NCT04771572 2026-05-05
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
Phase 1 Recruiting
NCT05010005 2026-04-09
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT02512497 2025-09-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT05823571 2025-09-18
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT05225584 2025-03-19
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Kymera Therapeutics, Inc.
Phase 1 Completed
NCT04526795 2024-12-12
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03989466 2024-10-10
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02689453 2022-04-29
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04823091 2022-03-16
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT01094860 2020-02-11
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00124189 2015-12-24
Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
Geron Corporation
Phase 1 Completed
NCT00671112 2015-10-28
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00749502 2013-07-25
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
Tesaro, Inc.
Phase 1 Completed